Vivakor (VIVK) Stock Surges 75% After $40M Oil Trading Deal

15 October 2025

Stock Rally: On Oct. 15, 2025 Vivakor shares spiked, opening around $0.25 and hitting ~$0.37 intraday before settling near $0.28 ^[1]. This was a ~50–75% jump over the prior day’s close (~$0.19), with massive trading volume (~230 million shares) ^[2].
New Funding: Vivakor announced a $40 million commodity credit facility for its crude-oil trading arm ^[3]. In late Sept, it had also signed a term sheet to raise $23 million via convertible preferred stock to expand its oil marketing and remediation businesses ^[4].
Nasdaq Compliance: The company just received a 180-day extension (to Mar 16, 2026) from Nasdaq to meet the $1.00 minimum bid price ^[5]. Vivakor needs a ten-day stretch above $1.00 (or a reverse stock split) to avoid delisting.
Special Dividend: Vivakor re-scheduled a special dividend (paid in shares of Adapti, Inc.) to Oct. 31, 2025 ^[6]. This dividend (about 0.0074 Adapti shares per Vivakor share) is roughly worth $0.2–$0.5 million in total ^[7].
Leadership Moves: In August the company added energy veterans as COO and CFO ^[8], aiming to improve operations and financial discipline.

In mid-October Vivakor’s stock surged amid fresh corporate deals. On Oct. 15 the company revealed it had signed a non-binding term sheet for a $40M commodity intermediation facility ^[9]. This arrangement (with a wholesale credit provider) is intended to underwrite letters of credit, bonds or cash deposits to support Vivakor Supply & Trading, LLC’s physical crude oil purchases ^[10]. CEO James Ballengee said the deal “highlights our growth initiative for Vivakor’s trading segment,” enabling them to integrate more oil volumes across their trucks and facilities and “driv[e] immediate accretive revenue while diversifying and expanding our crude oil marketing operations” ^[11]. The facility would have a one-year term (target close: Oct. 30, 2025) and up to $40M in available credit support ^[12].

This announcement built on other recent funding news. On Sept. 29 Vivakor signed a term sheet to issue $25M of new convertible preferred stock in exchange for up to $23M in funding ^[13]. Under that deal, about $15M of proceeds will seed a dedicated trading credit line for Vivakor’s oil marketing division, $3M will bolster general working capital, and at least $5M of oil and equipment will go to its remediation segment ^[14]. Ballengee explained the package “would directly support two of our expanding business segments, crude oil marketing and remediation,” creating synergies across Vivakor’s network of trucks and terminals ^[15]. COO Les Patterson added that the capital and accompanying exclusive trucking commitments from the partner would “bring in both capital and assets that can be deployed immediately to enhance our crude oil throughput and remediation capabilities,” calling it “a catalyst for deeper vertical integration across our platform” ^[16].

Vivakor has also been forging partnerships. In early September it entered a joint venture with tech firm Neuralix to deploy AI analytics in its midstream oil operations ^[17]. The plan is to use Neuralix’s platform for smarter routing of pipeline and trucking routes, predictive maintenance, and dynamic scheduling. “By integrating this powerful AI into our core operations, we can unlock efficiencies, improve service capabilities, and strengthen our position as a forward-thinking energy operator,” Ballengee said ^[18]. Neuralix’s CEO Vikram Jayaram commented that the deal will turn “complex midstream operations into a source of predictive insight and measurable ROI,” helping shape “a more resilient, efficient, and sustainable energy future” ^[19].

Stock Performance: Vivakor’s stock action reflects these developments but also high risk. According to market data, VIVK closed around $0.28 on Oct. 15 ^[20], well above the ~$0.19 close on Oct. 14 ^[21]. However, the stock has been extremely volatile: it peaked at about $1.68 earlier in 2025 (52-week high) and plunged below $0.20 before the mid-October rally ^[22] ^[23]. For the week and month leading into Oct. 15, VIVK was generally flat-to-down, trading mostly in the $0.20–$0.30 range ^[24]. The Oct. 15 surge came with huge volume (~229.7M shares) ^[25], far exceeding typical daily volume (~a few million). By Oct. 16 morning, some sources reported the stock around $0.30 ^[26] (a ~75% gain day-on-day). Vivakor remains a micro-cap with a market value under $10 million ^[27].

Expert Commentary: Company executives paint an upbeat picture. Ballengee and new COO/COO appointees emphasize growth and integration. Ballengee said the combined deals “create synergies across all of our operating divisions” and will set the stage for “long-term value creation” ^[28]. Newly hired CFO Kimberly Hawley remarked that Vivakor is “at an inflection point,” and she will focus on enhancing financial discipline and transparency ^[29]. These comments underscore management’s commitment to operational execution and tighter financial controls as the business scales.

Not all analysts are convinced, however. In technical analyses, VIVK is viewed as highly speculative. For example, StockInvest.us (a market research site) warns that Vivakor “holds several negative signals and is within a very wide and falling trend,” concluding a “negative evaluation” of the stock ^[30]. Indeed, the share price is far below Nasdaq’s $1 minimum bid. Nasdaq has given Vivakor until March 16, 2026 to get its stock above $1 for ten straight days ^[31]. If that fails, Vivakor indicated it may execute a reverse split to comply ^[32]. Meanwhile, the company’s fundamentals remain weak: Vivakor reported ~$89.8 million in revenue for full-year 2024 but a net loss of about $23.0 million (nearly twice its 2023 loss) ^[33]. The large losses and tiny market cap underline the risk that investors face.

Outlook: The recent deals give bullish investors hope that Vivakor can turn its asset network and new funding into profits. Some forecast services see significant upside: one model (StockScan) projects Vivakor’s share average could reach ~$0.76 by end-2025 (implying +159% from current levels) and over $1 by 2027 ^[34] ^[35]. These bullish scenarios assume the company’s crude-oil marketing and logistics push succeeds and that oil markets stay firm. In that view, the Oct. 15 rally is the start of a sustained recovery.

Conversely, bears note that trading thinly and under heavy dilution could keep pressure on the stock. The special dividend (in Adapti stock) was valued at only a few cents per Vivakor share ^[36], offering minimal tangible benefit. Analysts caution that until Vivakor can consistently generate profits or lift its price above compliance levels, speculative spikes may be followed by steep falls. For now, VIVK is navigating a high-stakes turnaround: each side – bullish and bearish – has ample arguments. Investors will be watching closely whether the new oil trading facility truly boosts revenue, or whether the Nasdaq compliance clock forces more dilution (like a reverse split) that erodes shareholder value.

Sources: Recent Vivakor press releases and SEC filings ^[37] ^[38] ^[39]; market data from StockAnalysis and Investing.com ^[40] ^[41]; analysis commentary from StockInvest.us ^[42]; forecasting from StockScan ^[43] ^[44].

Vivakor secures long-term oil sands supply and lease agreement at its Utah facility

Watch this video on YouTube.

References

Tags:

Marcin Frąckiewicz Latest posts

CEO of TS2 Space and founder of TS2.tech. Expert in satellites, telecommunications, and emerging technologies, covering trends in space, AI, and connectivity.

View all

MercadoLibre (MELI) Stock Dips Amid Brazil Competition – Analysts Eye Long-Term Upside

16 October 2025

BMY Tops Partha Mohanram P/B Growth Model in Validea Guru Analysis
October 15, 2025, 8:12 PM EDT. Validea's guru fundamental report ranks BRISTOL-MYERS SQUIBB CO (BMY) highly under the P/B Growth Investor model developed by Partha Mohanram. As a large-cap growth stock in the Biotechnology & Drugs space, BMY earns an 88% rating on the model, signaling strong interest from this strategy based on a low book-to-market profile paired with growth traits. The score reflects PASS readings for factors like Book/Market Ratio, Return on Assets, Cash Flow from Operations to Assets, and others, with the notable exception of R&D to Assets which fails. The analysis highlights that the firm's fundamentals align with the model's emphasis on valuation and growth, contributing to the high score despite some variance areas.
BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model Endorses Bristol-Myers Squibb
October 15, 2025, 8:10 PM EDT. Bristol-Myers Squibb (BMY) ranks highest among Validea's 22 guru strategies under the P/B Growth Investor model by Partha Mohanram. The growth model targets low book-to-market stocks with characteristics linked to sustained future growth. BMY scores 88%, suggesting notable interest from the strategy, with scores above 90% signaling strong interest. The test table shows BMY passing key criteria, including Book/Market Ratio PASS, Return on Assets PASS, Cash Flow from Operations to Assets PASS, CF Ops to Assets vs ROA PASS, ROA Variance PASS, Sales Variance PASS, Advertising to Assets PASS, Capital Expenditures to Assets PASS, and R&D to Assets PASS. Framed as a large-cap growth stock in Biotechnology & Drugs, the report highlights favorable fundamentals and valuation under Mohanram's model, per Validea's methodology.
BMY Factor-Based Analysis Shows High Growth Signal Under Mohanram Model
October 15, 2025, 8:08 PM EDT. Validea's guru analysis for BRISTOL-MYERS SQUIBB CO (BMY) shows the Partha Mohanram P/B Growth Investor model rates BMY at 88%, indicating notable interest from this growth framework. The model targets low book-to-market stocks with traits linked to sustained growth. BMY is described as a large-cap growth stock in the Biotechnology & Drugs industry. Under this strategy, a score of 80%+ signals interest, with 90%+ signaling strong interest. In the summary table, most tests are PASS: BOOK/MARKET RATIO, RETURN ON ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS, CASH FLOW FROM OPERATIONS TO ASSETS VS. RETURN ON ASSETS, ROA VARIANCE, SALES VARIANCE, ADVERTISING TO ASSETS, CAPITAL EXPENDITURES TO ASSETS. The only cited shortcoming is RESEARCH AND DEVELOPMENT TO ASSETS: FAILED. Background on Partha Mohanram and Validea's approach is included.
BMY: Partha Mohanram Growth Model Signals Strength in Validea's Guru Analysis
October 15, 2025, 8:06 PM EDT. Validea's guru-based assessment rates BRISTOL-MYERS SQUIBB CO (BMY) highly under the Partha Mohanram P/B Growth Investor model. The stock is highlighted as a large-cap growth name in Biotechnology & Drugs, with an 88% strategy score and a history of strong fundamentals. The model targets low book-to-market, growth-oriented stocks, and flags BMY as meeting key tests across metrics such as Book/Market Ratio, Return on Assets, Cash Flow from Operations to Assets, and R&D to Assets. While some criteria are weighted differently, the overall takeaway is that BMY displays positive fundamental signals with favorable growth-oriented metrics. Investors should note the model's emphasis on sustained growth indicators rather than short-term momentum, and consider BMY within a diversified growth-focused portfolio.
BMY Factor-Based Stock Analysis: Partha Mohanram Growth Model (Validea)
October 15, 2025, 8:04 PM EDT. Validea's guru analysis rates BRISTOL-MYERS SQUIBB CO (BMY) highly under the Partha Mohanram P/B Growth Investor model, with an 88% score signaling potential in a low book-to-market, growth-focused framework. The model seeks stocks with low book-to-market ratios and sustained growth characteristics. BMY, a large-cap in the Biotechnology & Drugs space, earns PASS on tests like BOOK/MARKET RATIO, RETURN ON ASSETS, and CASH FLOW FROM OPERATIONS TO ASSETS. The report emphasizes that scores at or above 80% indicate interest, with above 90% signaling strong interest. Readers get context on Mohanram and Validea's framework, which aggregates insights from published guru strategies. Investors can weigh BMY's fundamentals against this factor-based growth approach and the stock's valuation signals.

Vivakor (VIVK) Stock Surges 75% After $40M Oil Trading Deal – Bulls & Bears Weigh In

References

Tags:

Related Articles

MercadoLibre (MELI) Stock Dips Amid Brazil Competition – Analysts Eye Long-Term Upside

Pinnacle Food Group (PFAI) Stock Explodes 140% on Trade News – What’s Behind the Rally?

Mawson Infrastructure (MIGI) Stock Skyrockets on Crypto Rally and Executive Shakeup

Sea Limited (SE) Stock Tumbles Nearly 10% as Analysts Debate Shopee’s Growth vs. High Valuation

Theriva Biologics (TOVX) Stock Soars 92% on Oncolytic Virus Trial News – Can the Rally Last?

Stock Market Today